" class="no-js "lang="en-US"> Drug Development Archives - Page 32 of 40 - Medtech Alert
Tuesday, June 30, 2026

Sort by:

Date

Top Post

Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine

Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to […]

Lannett Announces Submission of Investigational New Drug (IND) Application for Biosimilar Insulin Glargine

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application […]

NHS Strikes Deal to Make PKU Drug Available For All

The NHS is set to make a drug for the rare, debilitating disorder phenylketonuria (PKU) […]

Evusheld Long-acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Independent FDA Study

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained  neutralising […]

Evusheld (Formerly AZD7442) Long-acting Antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19

AstraZeneca‘s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the […]

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Sosei Group Corporation (“the Company”; TSE: 4565) today announced it has received grant funding from […]

CHMP Recommends EU Approval of Actemra/RoActemra to Treat Patients with Severe COVID-19

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]

Metrion Biosciences Expands Ion Channel Drug Discovery Service Capabilities and In-house Expertise

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more